Singapore markets open in 1 hour 25 minutes

Roche Holding AG (RHHBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
388.000.00 (0.00%)
At close: 03:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close388.00
Bid0.00 x 0
Ask0.00 x 0
Day's range388.00 - 388.00
52-week range340.10 - 473.65
Avg. volume753
Market cap335.663B
Beta (5Y monthly)0.30
PE ratio (TTM)23.42
Earnings dateN/A
Forward dividend & yield9.97 (2.80%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Business Wire

    Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

    SOUTH SAN FRANCISCO, Calif., June 16, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimer’s Institute, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-o

  • Business Wire

    Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting

    SOUTH SAN FRANCISCO, Calif., June 10, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it is presenting new long-term follow-up results and subanalyses from clinical trials of its approved therapies, as well as data on investigational medicines from its broad blood cancer portfolio, at the European Hematology Association (EHA) 2022 Congress in Vienna. Data include five-year results from the Phase III CLL14 study of fixed-duration Venclexta® (venetoc

  • Business Wire

    FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)

    SOUTH SAN FRANCISCO, Calif., May 31, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months old with spinal muscular atrophy (SMA). The approval is based on interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that the majority of pre-symptomatic babies treated with Evrysdi achieved key mil